Copper Single-Atom MOF for Ultrasound-Enhanced Nanocatalytic Cancer Therapy

Study Background and Research Question

Chemodynamic therapy (CDT) has emerged as a promising strategy for cancer treatment due to its ability to generate highly toxic reactive oxygen species (ROS) within the tumor microenvironment (TME). The core mechanism relies on Fenton or Fenton-like reactions catalyzed by transition metal ions, which convert endogenous hydrogen peroxide (H₂O₂) into hydroxyl radicals (•OH) that induce tumor cell apoptosis. However, the efficacy of CDT is often impaired by the low H₂O₂ concentrations and high levels of reducing substances such as glutathione (GSH) present in tumors. These conditions diminish ROS production and limit therapeutic outcomes. The primary research question addressed by Wang et al. is how to design a nanocatalyst that maximizes catalytic efficiency, minimizes toxicity, and enables precise imaging-guided therapy in this challenging biochemical milieu.

Key Innovation from the Reference Study

The study presents a copper single-atom-based MOF nanoenzyme (SAzyme) termed FNUC (FA-NH₂-UiO-66-Cu). This system strategically incorporates several advances:

• Single-atom Cu sites: Unlike traditional metal clusters, single-atom dispersion on the MOF ensures nearly every copper atom is catalytically active, drastically improving atom utilization and reducing overall metal content and associated toxicity.
• Glutathione depletion and peroxidase-like activity: The FNUC design leverages copper's redox cycling between Cu²⁺ and Cu⁺ states to deplete intracellular GSH and continuously generate •OH within the mildly acidic TME.
• Ultrasound (US) enhancement: Application of ultrasound irradiation accelerates the catalytic process via the cavitation effect, further increasing •OH production.
• NIR-II fluorescence imaging: The MOF is modified with the near infrared fluorescent dye IR-1061, enabling deep-tissue, high-contrast in vivo imaging to confirm tumor targeting and monitor therapeutic distribution.

This integrated approach addresses both the biochemical barriers to CDT and the need for non-invasive, real-time imaging.

Methods and Experimental Design Insights

The researchers synthesized FNUC by coordinating single copper atoms within the amino-functionalized UiO-66 MOF, followed by folic acid (FA) modification for tumor targeting. Comprehensive characterization included SEM, TEM, STEM, EDS, XRD, UV–vis, and FT-IR analyses to confirm structure, elemental composition, and successful copper incorporation. X-ray absorption spectroscopy (XAS), XANES, and EXAFS provided atomic-level insight into copper's coordination environment and single-atom dispersion.

Key functional assessments included:

• Measurement of peroxidase-like activity and Michaelis-Menten kinetics for •OH generation in the presence and absence of ultrasound.
• Glutathione depletion assays to quantify the nanozyme's impact on intracellular redox status.
• In vitro cytotoxicity and apoptosis assays in tumor cell lines to assess therapeutic efficacy.
• In vivo studies in tumor-bearing mice, combining NIR-II fluorescence imaging (using IR-1061 labeling) with therapeutic interventions to track biodistribution and treatment outcomes.

Protocol Parameters

• FNUC synthesis: Copper loading optimized to maximize single-atom dispersion; detailed MOF activation and ligand exchange protocols using NH₂-UiO-66 scaffold.
• Ultrasound irradiation: Applied at 1 MHz, 1.5 W/cm² for 5 minutes during in vitro and in vivo activation to enhance cavitation-mediated ROS generation.
• NIR-II imaging: IR-1061 conjugation to FNUC; excitation/emission parameters set according to the product information and validated protocol settings from internal benchmarking studies.
• GSH depletion and ROS assays: Standardized spectrophotometric and fluorescence-based methods, with control for TME-mimicking pH and H₂O₂ levels.

Core Findings and Why They Matter

According to the reference study, the FNUC nanozymes exhibit several notable outcomes:

• Efficient glutathione depletion, overcoming a major resistance mechanism in the TME and allowing sustained ROS production.
• High •OH generation rates under ultrasound, with a low Michaelis constant indicating strong catalytic affinity for substrates even at low H₂O₂ concentrations typical of tumors.
• NIR-II fluorescence imaging—enabled by IR-1061—demonstrates clear tumor accumulation and retention, supporting precise delivery and monitoring.
• In vivo, FNUC combined with ultrasound leads to significant tumor inhibition compared to controls, confirming the synergy between catalytic therapy and imaging guidance.

Collectively, these findings show that single-atom Cu-based MOF nanozymes can achieve high specificity, minimize off-target toxicity, and allow real-time imaging—key goals for translational cancer nanomedicine.

Comparison with Existing Internal Articles

The integration of IR-1061 as a near infrared fluorescent dye in this study directly extends previous advances in molecular imaging with organic fluorophores. Internal articles such as "IR-1061: Near Infrared Fluorescent Dye for Deep Tissue Imaging" and "IR-1061 Near Infrared Fluorescent Dye for Deep Tissue Imaging" have established IR-1061's suitability for deep tissue, high-contrast imaging in vivo. The current reference paper builds on these protocols by demonstrating that IR-1061-conjugated FNUC enables robust NIR-II imaging of tumor sites, confirming and extending the utility of this dye in multifunctional nanotherapeutic strategies. Furthermore, the molecular design principles highlighted in "Rational Design Enhances NIR-II IR-1061 Liposome Imaging Performance" are reflected in the conjugation and optimization of IR-1061 within the MOF-based system, maximizing imaging signal and biodistribution.

Limitations and Transferability

Despite these advances, several limitations remain. The in vivo studies, while demonstrating efficacy and imaging precision, are limited to murine models and cannot fully predict long-term safety or immune interactions in humans. The ultrasound parameters and tumor-targeting efficiency may require further adaptation for clinical translation. Additionally, while copper single-atom nanozymes reduce overall metal content, their long-term fate and potential off-target effects need further investigation. Transferability to other disease models or targets will depend on the modularity of the MOF scaffold and conjugation chemistry, which warrants additional validation.

Research Support Resources

To support similar workflows in molecular imaging and catalytic therapy research, investigators can use IR-1061 (SKU C8242) as a near infrared fluorescent dye for biomedical research. This dye offers strong NIR-II fluorescence, is specifically optimized for in vivo optical and molecular imaging, and is reliably soluble in DMSO but insoluble in ethanol and water, as reported in the product information. APExBIO provides quality control and storage guidance to ensure experimental reproducibility. For additional protocols and troubleshooting strategies, see the linked internal articles on IR-1061 optimization and application in deep tissue imaging. Researchers are encouraged to follow validated handling and imaging protocols to maximize data quality and reproducibility in nanomedicine studies.